Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters.
Abstract: The most prevalent TDR drug resistance mutations, in both LP and NLP, were K103N/S, T215rev, T215FY, M184I/V, M41I/L, M46I/L, and L90M.
Prevalence and patterns of HIV drug resistance in patients with suspected virological failure in North-Western Tanzania.
PMID: 35107140
2022
The Journal of antimicrobial chemotherapy
Abstract: Common mutations in RT were M184V (75%), T215Y (41.1%), K103N (39.3%), M41L (32.1%), D67DN (30.3%), G190A (28.6%) and A98G (26.8%).
Table: T215Y
Discussion: The most plausible explanations for the occurrence of T215Y, D67N, M41L, K219K/Q and K70R TAMs among patients with tenofovir disoproxil fumarate-based ART regimen failure are that these TAMs were transmitted drug resistance RAMs (TDR-RAMs) or were selected by exposure to undisclosed thymidine analogue-based regimens.
Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.
PMID: 34897227
2022
Journal of acquired immune deficiency syndromes (1999)
Table: T215F/Y
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes.
Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria.
PMID: 34741609
2022
The Journal of antimicrobial chemotherapy
Result: Sixteen participants had all of the TAM 1 pathway mutations (M41L, L210W and T215Y), 11 had all of the TAM 2 pathway mutations (D67N, K70R, T215F and K219Q/E) and four had the mutations for both pathways.
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation.
PMID: 33315694
2021
Journal of acquired immune deficiency syndromes (1999)
Table: T215Y/F
High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.
Result: The most frequently detected DRMs were M184I/V (68/82; 82.9%), K70E/R (16/82; 19.5%), and T215F/Y (17/82; 20.7%) to NRTI and K103N/S (51/82; 62.1%), P225H (15/82; 18.2%), and V106A/I/M (11/82; 13.4%) to NNRTI (Figure 1).
Result: Thymidine analog mutations (TAM) were detected in 35.4% of the individuals [17.1% (14/82) TAM-1 (including M41L, L210W, and T215Y) and 20.7% (17/82) TAM-2 (including D67N, K70R, T215F, and K219Q/E
Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance.
Method: T215 mutations other than T215Y/F were called T215 revertants because they often emerge in individuals initially infected with a virus containing T215Y/F.
Method: Thymidine-analog mutations were defined as the NRTI-SDRMs M41L, D67N/G/E, K70R, L210W, T215Y/F/S/C/D/E/I/V, and K219Q/E/N/R.
Discussion: The continued prevalence of thymidine analog mutations in RTI-naive persons since 2009 despite the decline in thymidine analog use has been reported in several studies and reflects the fact that with the exception of
High HIV-1 Virological Failure and Drug Resistance among Adult Patients Receiving First-Line ART for At least 12 Months at a Decentralized Urban HIV Clinic Setting in Senegal before the Test-and-Treat.
Result: K65R/E/N and K70E mutations conferred resistance to TDF and M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E conferred resistance to AZT.
Result: M184 V/I 87 (28.8%), K65R/E/N 27 (8.9%), L74 V 3 (1.0%), and Y115F 12 (4.0%) were the mutations conferring resistance to NRTIs, along with thymidine analog mutations (TAMs) M41L 14 (4.6%), D67N 17 (5.6%), K70R 20 (6.6%), L210W
HIV mutation literature information.
PMID: 
2022
Frontiers in microbiology
Browser Board
Co-occurred Entities
Filtrator
ViMRT